Who is sponsoring NCT05899400?

NCT05899400 is sponsored by Diascopic, LLC.

What drugs are being tested in NCT05899400?

Interventions in NCT05899400: Diascopic iON Image Analysis System.

What condition does NCT05899400 study?

NCT05899400 studies Tuberculosis, Pulmonary.

Is NCT05899400 still recruiting?

NCT05899400 is currently completed. Last updated 12 June 2023.

Last reviewed 2023-06-12 · How we verify

NCT05899400

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides

Completed Last updated 12 June 2023

What this trial tests

trial testing Diascopic iON Image Analysis System in Tuberculosis, Pulmonary in 400 participants. Completed in 31 December 2022.

Timeline

15 September 2019

Primary endpoint
31 October 2022

31 December 2022

Quick facts

Lead sponsor	Diascopic, LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	400
Start date	15 September 2019
Primary completion	31 October 2022
Estimated completion	31 December 2022
Sites	1 location across Uganda

Drugs / interventions tested

Diascopic iON Image Analysis System

Conditions studied

Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →

Sponsor

Diascopic, LLC

Who can join

Eligibility, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tuberculosis, Pulmonary

Currently open trials in the same condition.

NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05899400 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Diascopic, LLC
Last refreshed: 12 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing